PCSK9 and hyperlipidemia: Future studies may extrapolate this work by investigating β-cell survival and function changes in response to new therapeutic approaches such as the combined use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and statins for treating hyperlipidemia.